<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>At Saitama <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Center a Phase II study of <z:chebi fb="0" ids="36373">Vindesine</z:chebi> was carried out in 18 patients with <z:e sem="disease" ids="C0848852,C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancy</z:e> being refractory to standard chemotherapies </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="36373">Vindesine</z:chebi> (VDS) was given weekly at a dose of 3 mg/m2 as single-agent chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>One cytoreduction effect (CE) in 5 patients with <z:hpo ids='HP_0011009'>acute</z:hpo> lympho blastic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, two CEs in 2 patients with <z:hpo ids='HP_0011009'>acute</z:hpo> non-lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, one PR and one CE in 4 patients with <z:mp ids='MP_0005481'>CML</z:mp>/BC, three PRs in 3 patients with diffuse non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) of large cell type, one CR in 2 patients with lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and one PR in 2 patients with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were obtained </plain></SENT>
<SENT sid="3" pm="."><plain>VDS was discontinued in two patients because of neurologic toxicities such as <z:e sem="disease" ids="C0042024" disease_type="Disease or Syndrome" abbrv="">incontinence of urine</z:e>, <z:hpo ids='HP_0003270'>abdominal distension</z:hpo>, and severe <z:hpo ids='HP_0002019'>constipation</z:hpo> </plain></SENT>
</text></document>